Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-2446PMID 17606722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

  2006cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications

  2005cited by this paper
• Methodological challenges in the evaluation of prognostic factors in breast cancer

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Mechanisms of cancer: multidrug resistance

  2004cited by this paper
• Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.

  2001cited by this paper
• Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer

  2001cited by this paper
• Sample size considerations for the evaluation of prognostic factors in survival analysis.

  2000cited by this paper
• Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.

  1998cited by this paper
• Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.

  1998cited by this paper
• Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.

  1996cited by this paper
• Preferential expression of the multidurg‐resistance‐associated protein (MRP) in adenocarcinoma of the lung

  1995cited by this paper
• Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.

  1995cited by this paper

• Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives

  2025cites this paper
• Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decades.

  2025cites this paper
• Action against thoracic cancers: recent achievements and perspectives.

  2024cites this paper
• Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer

  2023cites this paper
• Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum‐based doublet chemotherapy

  2022cites this paper
• Lung Cancer in Austria.

  2021cites this paper
• Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.

  2021cites this paper
• CircABCC2 Regulates Hepatocellular Cancer Progression by Decoying MiR-665

  2019cites this paper
• How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions.

  2019cites this paper
• Chemosensitivity and survival of non-small cell lung carcinoma patients receiving neoadjuvant therapy depend on the expression of multidrug efflux transporters

  2019cites this paper
• Adjuvant Therapy in Patients With Completely Resected Non–small‐cell Lung Cancer: Current Status and Perspectives

  2019cites this paper
• Clinical relevance of the multidrug resistance‑associated protein 1 gene in non‑small cell lung cancer: A systematic review and meta‑analysis.

  2018cites this paper
• Prognostic role of multidrug resistance-associated protein 1 expression and platelet count in operable non-small cell lung cancer.

  2018cites this paper
• Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.

  2018cites this paper
• [Current knowledge on perioperative treatments of non-small cell lung carcinomas].

  2017cites this paper
• Prognostic value of MRP , LRP and Pgp in patients with non-small cell lung cancer

  2017cites this paper
• Current knowledge on perioperative treatments of non-small cell lung carcinomas

  2017cites this paper
• ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

  2016cites this paper
• Chemotherapy Resistance in Lung Cancer.

  2016cites this paper
• Cisplatin resistance and opportunities for precision medicine.

  2016cites this paper
• Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis

  2015cites this paper
• Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer.

  2015cites this paper
• Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.

  2015cites this paper
• Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways.

  2015cites this paper
• MRP1 expression in bronchoalveolar lavage cells in subjects with lung cancer who were chronically exposed to arsenic

  2015cites this paper
• Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

  2015cites this paper
• WITHDRAWN: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways.

  2014cites this paper
• Importance of ABCC1 for cancer therapy and prognosis

  2014cites this paper
• TNM classification and clinicopathological factors: what is helpful for adjuvant chemotherapy decision after lung cancer resection?

  2014cites this paper
• MRP1 and GSTp1 expression in non-small cell lung cancer does not correlate with clinicopathological parameters: A Slovakian population study.

  2014cites this paper
• Facteurs de résistance à la chimiothérapie à base de sels de platine dans les cancers bronchiques non à petites cellules : Rôle de la voie Sonic Hedgehog dans la chimiorésistance

  2014cites this paper
• Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma

  2014cites this paper
• Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.

  2014cites this paper
• Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

  2014cites this paper
• Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy

  2013cites this paper
• Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo

  2013cites this paper
• HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein.

  2013cites this paper
• Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients.

  2013cites this paper
• Současné trendy adjuvantní chemoterapie u nemalobuněčného karcinomu plic

  2013cites this paper
• Charakterisierung von in vivo Modellen des humanen nicht-kleinzelligen Lungenkarzinoms zur Therapieoptimierung

  2012cites this paper
• Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes

  2012cites this paper
• Developments in the treatment of early NSCLC: when to use chemotherapy.

  2012cites this paper
• Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

  2012cites this paper
• Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.

  2012cites this paper
• Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

  2012cites this paper
• Biochemistry and Pharmacology of Human ABCC1/MRP1 and Its Role in Detoxification and in Multidrug Resistance of Cancer Chemotherapy

  2012cites this paper
• [Transmembrane transporters ABCC - structure, function and role in multidrug resistance of cancer cells].

  2011cites this paper
• The Evolving Role of Chemotherapy and Predictive Markers in Early-stage Non-small-cell Lung Cancer

  2011cites this paper
• Predictive markers in the adjuvant therapy of non-small cell lung cancer.

  2011cites this paper
• cartographie moléculaire de routine des cancers bronchiques : les limites méthodologiques

  2011influential citation
• MicroRNA Expression and Outcome in Resected NSCLC—Response

  2011cites this paper
• Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

  2011cites this paper
• Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer

  2011cites this paper
• [Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].

  2011cites this paper
• Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma

  2011cites this paper
• How close are we to customizing chemotherapy in early non-small cell lung cancer?

  2011influential citation
• Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research

  2011cites this paper
• Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  2011cites this paper
• Quantitative immunohistochemistry in lung cancer: clinical perspective.

  2010influential citation
• Quantitative analysis of cisplatin sensitivity of human esophageal squamous cancer cell lines using in‐air micro‐PIXE

  2010cites this paper
• Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.

  2010cites this paper
• Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

  2010cites this paper
• MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

  2010cites this paper
• A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  2010cites this paper
• Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?

  2010cites this paper
• MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

  2010cites this paper
• Lung Cancer Resistance to Chemotherapy

  2010cites this paper
• Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.

  2010cites this paper
• Mutations in Keap1 are a potential prognostic factor in resected non‐small cell lung cancer

  2010cites this paper
• Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

  2009cites this paper
• Update on Anti-EGFR Therapy

  2009cites this paper
• Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.

  2009cites this paper
• Expression of ABC transporters, p53, Bax, Bcl-2 in an archival sample of non-small cell lung cancer bearing a deletion in the EGFR gene.

  2009cites this paper
• Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers

  2009cites this paper
• Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond

  2009cites this paper
• First- and second-line therapy for advanced nonsmall cell lung cancer

  2009cites this paper
• FUNCTIONAL ANALYSIS OF AN α-HELICAL REGION IN THE HUMAN MULTIDRUG AND ORGANIC ANION TRANSPORTER MRP1

  2009cites this paper
• [Not Available].

  2009cites this paper
• Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy

  2009cites this paper
• Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.

  2009cites this paper
• Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

  2009cites this paper
• Update on Anti-EGFR Targeted Therapy

  2009cites this paper
• The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer

  2008cites this paper
• Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.

  2008cites this paper
• Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives

  2008cites this paper
• Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer.

  2008cites this paper
• Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.

  2008cites this paper
• Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise

  2008cites this paper
• [Towards customized therapy for non small cell lung cancer].

  2008cites this paper